Phaseline

Targets › POLR1C

POLR1C (DNA-directed RNA polymerases I and III subunit RPAC1): drug programs, companies and trials

1 program from 1 company in 9 trials: 3 Phase 4, 2 Phase 3, 2 Phase 2, 2 Phase 1; Neurology, Infectious disease, Psychiatry; next expected readout Jan 2028.

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Common component of RNA polymerases I and III which synthesize ribosomal RNA precursors and short non-coding RNAs including 5S rRNA, snRNAs, tRNAs and miRNAs, respectively. (UniProt, O15160)

Open in Phaseline: the race on POLR1C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesEmtricitabine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2A, POLR1CPhase 3Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis …Jan 2028

Conditions

Pre-Exposure Prophylaxis of HIV Infection (2) Hiv (1) Alcohol Use, Unspecified (1) Pre-exposure Prophylaxis (1) HIV/AIDS (1) Long Covid (1) Mild Cognitive Impairment (MCI) (1) Healthy Volunteer (1)

Modalities

small molecule (1)

Companies

Gilead Sciences (1)

Related targets

POLR2A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.